Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Comparison of Freeze-Dried Amniotic and Collagen Membranes for Soft Tissue Healing After Grafted Implant Surgery (FDAM-CM)

10 giugno 2026 aggiornato da: RAJAS DENTAL COLLEGE AND HOSPITAL

Comparison of Freeze-Dried Amniotic Membrane (FD-AM) and Collagen Membrane (CM) in Soft Tissue Healing After Stage 1 Implant Surgery With Particulate Grafting: An In Vivo Study

The goal of this clinical trial is to learn whether Freeze-Dried Amniotic Membrane (FD-AM) or Collagen Membrane (CM) provides better soft tissue healing after Stage I dental implant surgery with particulate bone grafting in adults requiring implant treatment in bilateral posterior maxillary edentulous sites. It will also evaluate postoperative pain associated with the two membrane types.

The main questions it aims to answer are:

Does FD-AM result in improved early soft tissue healing compared with CM as assessed by the Early Healing Score (EHS)? Does FD-AM reduce postoperative pain compared with CM as assessed by the Visual Analogue Scale (VAS)?

Researchers will compare FD-AM and CM placed over grafted implant sites to determine whether one membrane provides superior healing outcomes and patient comfort.

Participants will:

Undergo Stage I implant surgery with particulate bone grafting. Receive FD-AM at one implant site and CM at the contralateral implant site according to the study randomization protocol.

Attend follow-up visits for assessment of soft tissue healing and postoperative pain.

Complete questionnaires related to pain and healing outcomes during the postoperative period.

Panoramica dello studio

Descrizione dettagliata

This prospective interventional in vivo study was conducted in the Department of Advanced Dental Sciences, Rajas Dental College and Hospital, to compare the effectiveness of Freeze-Dried Amniotic Membrane (FD-AM) and Collagen Membrane (CM) in promoting soft tissue healing following Stage I implant surgery with particulate bone grafting.

A total of 10 partially edentulous patients with bilateral posterior maxillary edentulous sites meeting the predefined inclusion and exclusion criteria were recruited. The study employed a split-mouth design in which each patient contributed two implant sites, allowing direct within-patient comparison of the two membrane types. One site received FD-AM and the contralateral site received CM according to a randomization protocol based on a simple coin toss performed by an independent individual not involved in surgery or outcome assessment.

The study included patients aged 25-55 years presenting with bilateral posterior maxillary edentulous areas, immediate implant placement requirements following extraction, or delayed implant placement in ridge defects requiring grafting. Patients with smoking history, pregnancy, systemic diseases affecting bone metabolism, active periodontal disease, infectious diseases, vitamin D deficiency, or known allergies to study materials were excluded.

All surgical procedures were performed under aseptic conditions using standard implant surgical protocols. Following implant placement, xenogeneic demineralized bone matrix graft material (Osseograft) was placed around the implant site as required. Platelet-Rich Fibrin (PRF) was prepared from autologous venous blood and used to enhance the regenerative environment. Barrier membranes were adapted over the grafted sites to facilitate guided bone regeneration and were followed by primary wound closure using interrupted sutures.

The primary outcome measure was soft tissue healing assessed using the Early Healing Score (EHS) by a blinded examiner. Secondary outcome assessment included postoperative pain evaluation using a Visual Analogue Scale (VAS) and structured questionnaires administered during follow-up visits.

The study aimed to determine whether FD-AM provides comparable or superior soft tissue healing compared with conventional collagen membranes. The results demonstrated favorable healing responses with both membrane types, characterized by adequate hemostasis, absence of significant inflammatory signs, and satisfactory epithelialization during the early healing period. The findings suggest that both FD-AM and CM are effective barrier membranes for supporting early soft tissue healing and guided bone regeneration around dental implants.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

10

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Tamil Nadu
      • Kavalkinaru, Tamil Nadu, India, 627105
        • Rajas Dental College and Hospital

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto

Accetta volontari sani

No

Descrizione

Inclusion Criteria:

  • Adults aged 25-55 years.
  • Male and female participants.
  • Bilateral posterior maxillary edentulous area in the premolar region (Bedrossian Zone 2 classification).
  • Patients with teeth requiring extraction and eligible for immediate implant placement in the bilateral posterior maxillary region.
  • Patients with ridge defects classified as Siebert Class II or Class III and eligible for delayed implant placement in the bilateral posterior maxillary region.

Exclusion Criteria:

  • Current smokers.
  • History of systemic diseases affecting bone turnover, including hyperthyroidism (T4 outside 5.0-12.0 μg/dL or T3 outside 80-220 ng/dL), Type I diabetes mellitus (HbA1c > 6%), Cushing's disease, or hyperlipidemia.
  • Pregnant women.
  • Lactating mothers.
  • Presence of periodontal disease.
  • Known allergy to study materials or medications.
  • Blood-borne infectious diseases, including HIV or HBsAg positivity.
  • Vitamin D level < 30 ng/mL.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione incrociata
  • Mascheramento: Separare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Freeze-Dried Amniotic Membrane (FD-AM) Group
Participants underwent Stage I implant surgery with particulate bone grafting at the implant site. Following graft placement, a Freeze-Dried Amniotic Membrane (FD-AM) was adapted and placed over the grafted area to facilitate guided bone regeneration and enhance soft tissue healing. Postoperative healing was evaluated using the Early Healing Score (EHS) and Visual Analogue Scale (VAS).
Freeze-Dried Amniotic Membrane (FD-AM) was placed over the particulate bone grafted implant site following Stage I implant surgery. The membrane was trimmed and adapted to cover the grafted area, serving as a barrier membrane for guided bone regeneration and promoting soft tissue healing during the postoperative period.
Altri nomi:
  • Amniotic Membrane FD-AM
Sperimentale: Collagen Membrane (CM) Group
Participants underwent Stage I implant surgery with particulate bone grafting at the implant site. Following graft placement, a Collagen Membrane (CM) was adapted and placed over the grafted area to facilitate guided bone regeneration and support soft tissue healing. Postoperative healing was evaluated using the Early Healing Score (EHS) and Visual Analogue Scale (VAS).
Collagen Membrane (CM) was placed over the particulate bone grafted implant site following Stage I implant surgery. The membrane was trimmed and adapted to cover the grafted area, serving as a barrier membrane for guided bone regeneration and supporting soft tissue healing during the postoperative period.
Altri nomi:
  • Collagen Barrier Membrane CM

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Early Healing Score
Lasso di tempo: 1 week and 2 weeks

Assessment and comparison of soft tissue healing around bone-grafted implant sites covered with Freeze-Dried Amniotic Membrane (FD-AM) and Collagen Membrane (CM) following Stage I implant surgery using the Early Healing Score (EHS). The EHS evaluates wound healing based on three clinical parameters:

Clinical Signs of Re-epithelialization (CSR): 0 = visible distance between incision margins; 3 = incision margins in contact; 6 = merged incision margins.

Clinical Signs of Haemostasis (CSH): 0 = bleeding at incision margins; 1 = presence of fibrin ; 2 = absence of fibrin. Clinical Signs of Inflammation (CSI): 0 = redness involving >50% of incision length and/or pronounced swelling; 1 = redness involving <50% of incision length; 2 = absence of redness along incision length.

The EHS is calculated as the sum of CSR, CSH, and CSI scores , where 0 represents the poorest healing and 10 represents ideal wound healing. Higher scores indicate better soft tissue healing outcomes.

1 week and 2 weeks

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Postoperative Pain Assessment Using Visual Analogue Scale (VAS)
Lasso di tempo: 1 week and 2 weeks
Assessment and comparison of postoperative pain at bone-grafted implant sites covered with Freeze-Dried Amniotic Membrane (FD-AM) and Collagen Membrane (CM) using the Visual Analog Scale (VAS). Participants rate pain intensity on a scale from 0 to 10, where 0 = no pain and 10 = worst imaginable pain. Higher scores indicate greater pain severity and a worse outcome.
1 week and 2 weeks

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Cattedra di studio: Alex M Muruppel, MDS, Rajas Dental College and Hospital

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

19 giugno 2025

Completamento primario (Effettivo)

27 gennaio 2026

Completamento dello studio (Effettivo)

18 febbraio 2026

Date di iscrizione allo studio

Primo inviato

6 giugno 2026

Primo inviato che soddisfa i criteri di controllo qualità

10 giugno 2026

Primo Inserito (Effettivo)

15 giugno 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

15 giugno 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

10 giugno 2026

Ultimo verificato

1 giugno 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • RDCH/PRL/IEC/D-0138/2024 (Altro identificatore: Rajas Dental College & Hospital Institutional Ethics Committee)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

Individual Participant Data (IPD) will not be shared because the study was conducted as part of an academic postgraduate research project, and no formal data-sharing plan was established. Participant confidentiality and privacy will be maintained in accordance with institutional ethics requirements.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi